Dizal Pharmaceutical

  • Sunvozertinib Tablets Approved in China for NSCLC by China NMPA

    Aug, 2023. China NMPA approved the Category 1 innovative drug Sunvozertinib Tablets (Chinese trade name:SHUWUZHE) of Dizal (Jiangsu) Pharmaceutical Co., Ltd for use in adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy. Non-small cell lung cancer (NSCLC) is the most common type of cancer in China, with the highest incidence and mortality rates. EGFR is the most common driver gene mutation in NSCLC, and the EGFR Exon20ins mutation is the most…